Find information on thousands of medical conditions and prescription drugs.

Danazol

Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the FDA as the first drug to treat specifically endometriosis, but its role as a treatment for endometriosis has been largely replaced by the GnRH agonists. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

The agent is fat-soluble, has a molecular weight of 337.5. Its CAS registry number is 17230-88-5.

Danazol decreases the pituitary hormones FSH and LH and exerts an antiproliferative effect upon the endometrium, leading to amenorrhea. This effect is useful for patients with endometriosis. Commonly, pelvic pain associated with endometriosis is improved as well.

Androgenic side effects are of concern as in sensitive female individuals, Danazol can enhance unwanted heir growth leading to hirsutism. On rare occasion, it may deepen the voice. Other side effects could be acne and oily skin. As Danazol is metabolized by the liver, it cannot be used by patients with liver disease, and long-term use needs to monitor liver function on a periodic basis. Some patients who use Danazol may experience weight gain and fluid retention.

Contrary to GNRH agonists Danazol does not induce osteoporosis. Also, symptoms of hot flashes tend to be less common or severe.

Danazol is contraindicated in pregnancy as it could masculinize a female fetus.

Danazol has been used for other indications, namely in the management of menorrhagia, of fibrocystic breast disease, and of hereditary angioedema.

In the USA, Danazol was initially marketed as Danocrine, before it became available as a generic drug.

Read more at Wikipedia.org


[List your site here Free!]


Intravaginal danazol gel acts locally to relieve endometriosis pain
From OB/GYN News, 10/1/04 by Patrice G.W. Norton

CHICAGO -- A novel formulation of intravaginal danazol significantly reduced chronic pelvic pain in a small study of women with endometriosis, Dr. Thomas Janicki said in a poster presentation at a meeting sponsored by the International Pelvic Pain Society.

Most importantly, there was a lack of systemic androgenic side effects, and low to undetectable plasma levels of danazol, indicating that the drug was acting locally, said Dr. Janicki, director of the Pelvic Pain Center at University Hospitals of Cleveland.

Treatment with oral danazol in women has been associated with excessive hair growth, weight gain, acne, and deepening of the voice.

The investigational preparation by FemmePharma Inc. of danazol gel that adheres to the vaginal wall was used in the study of 25 women with a prior surgical diagnosis of endometriosis and moderate to severe pain. Dr. Janicki received financial support for his study from FemmePharma and is a scientific advisor and stockholder in the company.

Of the women studied, 16 received 100 mg/day danazol for four menstrual cycles and 9 received 100 mg/day for three cycles and then switched to 200 mg/day for two additional cycles. The patients self-administered the danazol intravaginally with an applicator.

Pelvic pain was evaluated before, during, and after treatment using the Biberoglu and Behrman symptoms scale (BBSS), pain assessment questionnaires, and quality of life questionnaires.

There was a mean improvement of more than 50% in BBSS from baseline to the last visit at either 5 or 6 months (average 8.4 vs. 4.5, respectively). "The symptoms of dysmenorrhea, dyspareunia, pelvic pain, and pelvic tenderness all showed significant changes at the final visit compared with the first visit," Dr. Janicki said.

Pain assessment scores showed that average endometriosis pain experienced in the previous 4 weeks decreased by a mean 3.4 points from screening to end of treatment, and that worst endometriosis pain experienced in the previous 4 weeks decreased by 3.0 points.

On the quality of life questionnaire, 79% of women reported improvement from baseline.

One case each of mild facial acne, mild nausea, bloating, and mild abdominal pain, and three cases of vaginal irritation were reported. All of the women in the small, open-label, single-arm, multicenter study retained their menses and ovulation.

BY PATRICE G. W. NORTON

Contributing Writer

COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Danazol
Home Contact Resources Exchange Links ebay